See more : IMV Inc. (IMV.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Galileo Life Sciences, Inc. (MDRM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galileo Life Sciences, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Cora Gold Limited (CORA.L) Income Statement Analysis – Financial Results
- Sensorion SA (SENOF) Income Statement Analysis – Financial Results
- Black Iron Inc. (BKI.TO) Income Statement Analysis – Financial Results
- Hap Seng Plantations Holdings Berhad (5138.KL) Income Statement Analysis – Financial Results
- Empiric Student Property plc (EPCFF) Income Statement Analysis – Financial Results
Galileo Life Sciences, Inc. (MDRM)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://galileolife.com
About Galileo Life Sciences, Inc.
Galileo Life Sciences, Inc. operates in the telehealth and telemedicine industry. It operates a telehealth platform incorporating AI and IOT to get access to healthcare regardless of location and financial status. The company was formerly known as Modern Mobility Aids, Inc. and changed its name to Galileo Life Sciences, Inc. in March 2021. Galileo Life Sciences, Inc. was incorporated in 2007 and is based in Brampton, Canada.
| Metric | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.66K | 7.85K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 938.00 | 5.16K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 718.00 | 2.69K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 43.36% | 34.29% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 270.72K | 55.22K | 363.62K | 137.63K | 7.40K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 270.72K | 55.22K | 363.62K | 137.63K | 7.40K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 270.72K | 55.22K | 363.62K | 158.99K | 11.47K |
| Cost & Expenses | 270.72K | 55.22K | 363.62K | 159.93K | 16.63K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 649.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 649.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -270.72K | -270.72K | -55.22K | -363.62K | -158.28K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -9,557.67% | -111.81% |
| Operating Income | -271.37K | -55.22K | -363.62K | -158.28K | -8.78K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -9,557.67% | -111.81% |
| Total Other Income/Expenses | 23.13K | 23.13K | 2.61K | 0.00 | 0.00 |
| Income Before Tax | -248.24K | -52.60K | -363.62K | -158.28K | -8.78K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -9,557.67% | -111.81% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -248.24K | -52.60K | -363.62K | -158.28K | -8.78K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -9,557.67% | -111.81% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 123.36M | 195.48M | 195.48M | 146.11M | 22.66M |
| Weighted Avg Shares Out (Dil) | 123.36M | 195.48M | 195.48M | 146.11M | 22.66M |
Modern Mobility Aids, Inc. Appoints Olayinka Oyebola & Co. as New Auditor
Modern Mobility Aids Appoints Accomplished Industry Leader as New President
Modern Mobility Aids, Inc. Q3 2023 Update to Shareholders
Galileo Life Sciences Inc Continues Development of Its Telehealth Business Model And Announces an Opening Date for Its "VCPlus Clinics" in October 2021
Galileo Life Sciences Inc. (OTC:MDRM) Q2 2021 Provides Progress with Telehealth
Modern Mobility Aids Inc., Changes Name
Source: https://incomestatements.info
Category: Stock Reports